{"id":"W4412014975","doi":"10.1177/20406207251342199","title":"Clinical outcomes of high-risk patients with polycythemia vera after suboptimal response to first-line therapy who switched to ruxolitinib versus nonswitchers: results from the PV-Switch study","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"AOP Orphan; Swedish Orphan Biovitrum; Novartis Pharma; Galecto; Sierra Oncology; CTI Biopharma; Incyte; Celgene; Alexion Pharmaceuticals; Ariad Pharmaceuticals; Gilead Sciences; RWTH Aachen University; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Ruxolitinib; Phlebotomy; Internal medicine; Polycythemia vera; Thrombosis; Hematology; Retrospective cohort study; Myelofibrosis; Gastroenterology; Surgery; Bone marrow","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008432664,0.0002571788,0.0005356873,0.0003596435,0.0002695532,0.0006035198,0.0002607025,0.0004749948,0.0006984656],"category_scores_gemma":[0.00129711,0.0001457198,0.0005486615,0.0004168043,0.0002726712,0.0004574727,0.0003025704,0.0004412531,0.0001441752],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004124539,"about_ca_system_score_gemma":0.0002027746,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005391995,"about_ca_topic_score_gemma":0.0007696262,"domain_scores_codex":[0.999624,0.0001256405,0.00003693888,0.0001002391,0.0000581118,0.00005504943],"domain_scores_gemma":[0.998724,0.0002357056,0.0005399209,0.0000815945,0.00007624668,0.0003425243],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.005975617,0.0004007248,0.9867582,0.00002520882,0.0003204645,0.0001842753,0.00008669668,0.0001517721,0.0008766043,0.00001814968,0.0001743421,0.00502805],"study_design_scores_gemma":[0.0008687628,0.004234989,0.9929512,0.00001032903,0.0002159354,0.0006127273,0.0001150446,0.0004840882,0.0002543383,0.00003672038,0.0002045481,0.00001134517],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9996918,0.0001185675,0.00001919714,0.00001087932,0.000002810528,0.000007312564,0.00006270497,9.547842e-7,0.00008572861],"genre_scores_gemma":[0.999608,0.00004509811,0.0000218043,0.00002401945,0.00001032816,0.000006327345,0.0002482623,4.877058e-7,0.00003576524],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0008432664,"threshold_uncertainty_score":0.004459679,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02571890817822953,"score_gpt":0.3605291126465878,"score_spread":0.3348102044683583,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}